Cytokinetics (CYTK) Total Liabilities (2016 - 2024)
Historic Total Liabilities for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to $1.4 billion.
- Cytokinetics' Total Liabilities rose 2293.98% to $1.4 billion in Q3 2024 from the same period last year, while for Sep 2024 it was $1.4 billion, marking a year-over-year increase of 2293.98%. This contributed to the annual value of $1.2 billion for FY2023, which is 783.52% up from last year.
- Latest data reveals that Cytokinetics reported Total Liabilities of $1.4 billion as of Q3 2024, which was up 2293.98% from $1.4 billion recorded in Q2 2024.
- Cytokinetics' 5-year Total Liabilities high stood at $1.4 billion for Q3 2024, and its period low was $302.3 million during Q1 2020.
- For the 5-year period, Cytokinetics' Total Liabilities averaged around $836.7 million, with its median value being $740.0 million (2022).
- Its Total Liabilities has fluctuated over the past 5 years, first soared by 8874.71% in 2022, then surged by 763.36% in 2024.
- Cytokinetics' Total Liabilities (Quarter) stood at $420.4 million in 2020, then soared by 42.11% to $597.5 million in 2021, then skyrocketed by 87.91% to $1.1 billion in 2022, then rose by 7.84% to $1.2 billion in 2023, then grew by 19.77% to $1.4 billion in 2024.
- Its Total Liabilities was $1.4 billion in Q3 2024, compared to $1.4 billion in Q2 2024 and $1.2 billion in Q1 2024.